A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial

Bo Li, Qin Hua Jin, Yun Dai Chen, Chang Qian Wang, Bei Shi, Xi Su, Guo Sheng Fu, Yan Qing Wu, Xu Chen Zhou, Zu Yi Yuan, Bo Li, Qin Hua Jin, Yun Dai Chen, Chang Qian Wang, Bei Shi, Xi Su, Guo Sheng Fu, Yan Qing Wu, Xu Chen Zhou, Zu Yi Yuan

Abstract

Background: Earlier vascular healing after drug-eluting stent (DES) implantation may reduce the incidence of late stent thrombosis and provide theoretical evidence to shorten dual antiplatelet therapy duration in patients with high bleeding risks. The BuMA supreme stent is a newly developed DES-coated with the sirolimus by using the international patent electronic grafted eG™ technology. Previous randomized trials showed that BuMA stents had better stent-strut coverage at 3-month follow-ups, which were evaluated by optical coherence tomography (OCT). However, there have been a limited number of studies that are directly evaluating the extent of neointima formation at the first and second months after stent implantation in high-bleeding-risk patients with coronary artery disease. This clinical trial is designed to demonstrate the non-inferiority of the BuMA supreme stent compared to the XIENCE stent in early neointimal formation.

Methods/design: This is a prospective, multicenter, randomized trial. Forty patients will be assigned into the first-month OCT group, and another 40 patients into the second-month OCT group. The patients in each cohort will be randomized again into two groups in a 1:1 ratio, either being implanted with the BuMA Supreme stent or the Xience V/Prime/Xpedition stent. The primary endpoint is stent-strut neointimal coverage rate (%) at the first and second months, respectively. Secondary endpoints include neointimal hyperplasia area/volume, neointimal hyperplasia thickness, stent-strut malapposition rate, late lumen loss (LLL), restenosis rate, device/lesion/clinical success rate, device-oriented composite endpoints at the first and second months, stent thrombosis and other serious adverse events and bleeding events at follow-up.

Discussion: The results will provide the first accurate imaging evidence on neointimal formation of the BuMA Supreme stent and the Xience stent at 1-2 months post PCI. The result should inspire further exploration and adjustment of DAPT treatments.

Trial registration: ClinicalTrials.gov, ID: NCT02747329 . Registered on 21 April 2016. Last updated 17 May 2018.

Keywords: Bleeding risk; BuMA stent; Coronary artery disease; Malposition; Optical coherence tomography; Stent-strut coverage.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Design of study. OCT optical coherence tomography, CAD coronary artery disease
Fig. 2
Fig. 2
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure

References

    1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202. doi: 10.1016/j.jacc.2006.03.042.
    1. Urban P, Abizaid A, Chevalier B, Greene S, Meredith I, Morice MC, Pocock S. Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J. 2013;165(5):704–709. doi: 10.1016/j.ahj.2013.01.008.
    1. Chen M, Wang XG, Zheng B, Peng HY, Zhang XY, Zhang B, Huo Y. Investigation of long-term implantation of BuMA stent in a porcine coronary model. Chin Med J. 2012;125(22):4083–4087.
    1. von Birgelen C, Asano T, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez A, Janssens L, et al. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. EuroIntervention. 2018;13(17):2026–2035. doi: 10.4244/EIJ-D-17-00462.
    1. Qian J, Zhang YJ, Xu B, Yang YJ, Yan HB, Sun ZW, Zhao YL, Tang YD, Gao Z, Chen J, et al. Optical coherence tomography assessment of a PLGA-polymer with electro-grafting base layer versus a PLA-polymer sirolimus-eluting stent at three-month follow-up: the BuMA-OCT randomised trial. EuroIntervention. 2014;10(7):806–814.
    1. Urban P1, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–2047. doi: 10.1056/NEJMoa1503943.
    1. Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association; Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians; Editorial Board of Chinese Journal of Cardiology Chinese guideline for percutaneous coronary intervention. Zhonghua xin xue guan bing za zhi. 2016;44(5):382–400.
    1. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59(12):1058–1072. doi: 10.1016/j.jacc.2011.09.079.
    1. F P, Guagliumi G, Mintz GS, Costa M, Regar E, Akasaka T, Barlis P, Tearney GJ, Jang IK, Arbustini E, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J. 2012;33(20):2513–20. doi: 10.1093/eurheartj/ehs095.
    1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons. Thygesen K, Alpert JS, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–1598. doi: 10.1016/j.jacc.2012.08.001.
    1. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–668. doi: 10.1016/S0140-6736(07)60314-6.
    1. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52(14):1134–1140. doi: 10.1016/j.jacc.2008.07.006.
    1. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116(17):1952–1965. doi: 10.1161/CIRCULATIONAHA.106.683995.
    1. Pfisterer ME. Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. Circulation. 2008;118(11):1117–1119. doi: 10.1161/CIRCULATIONAHA.108.803627.
    1. Benezet-Mazuecos J, Ibanez B, Badimon JJ. Dual antiplatelet therapy and drug eluting stents: a marriage of convenience. Thromb J. 2007;5:15. doi: 10.1186/1477-9560-5-15.
    1. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ, SPIRIT IV Investigators Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58(1):19–25. doi: 10.1016/j.jacc.2011.02.022.
    1. Räber L, Magro M, Stefanini GG, Kalesan B, vanDomburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with earlygeneration drug-eluting stents: a prospective cohort study. Circulation. 2012;125(9):1110–1121. doi: 10.1161/CIRCULATIONAHA.111.058560.
    1. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33(10):1214–1222. doi: 10.1093/eurheartj/ehs086.
    1. Gutiérrez-Chico JL, Regar E, Nüesch E, Okamura T, Wykrzykowska J, di Mario C, Windecker S, van Es GA, Gobbens P, Jüni P, et al. Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. Circulation. 2011;124(5):612–623. doi: 10.1161/CIRCULATIONAHA.110.014514.
    1. Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen L, McClean D, Koolen J, et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011;4(9):992–1001. doi: 10.1016/j.jcin.2011.03.020.
    1. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, et al. Long-term follow-up of neointimal coverage of sirolimus-eluting stents—evaluation with optical coherence tomography. Circ J. 2009;73(12):2300–2307. doi: 10.1253/circj.CJ-08-1116.
    1. Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, Chen J, Hu FH, Yang WX, Mintz GS, et al. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chin Med J. 2012;125(6):970–976.
    1. Liu CF, Chen YD, Chen L, Sun ZJ, Gai LY, Liu HB, Tian F, Bai QC, Guo K. Optical coherence tomography for evaluation of neointimal proliferation after placement of a new drug eluting stent. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(5):1063–1065.
    1. Xu B, Gao R, Yang Y, Cao X, Qin L, Li Y, Li Z, Li X, Lin H, Guo Y, et al. Biodegradable polymer-based sirolimus-eluting stents with differing elution and absorption kinetics: The PANDA III Trial. J Am Coll Cardiol. 2016;67(19):2249–2258. doi: 10.1016/j.jacc.2016.03.475.
    1. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55(11):1093–1101. doi: 10.1016/j.jacc.2009.11.049.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する